Clinical Trial Update: A Phase 1 Study of AZD9833 in Japanese Women With ER Positive, HER2 Negative Advanced Breast Cancer [Phase 1]

View source ↗

Summary

This is an update on a Phase 1 study of AZD9833 in Japanese women with ER-positive, HER2-negative advanced breast cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AZD9833 (AZD9833)

Snippet

Sponsor: AstraZeneca | Conditions: ER+ HER2- Advanced Breast Cancer | Phase 1 | Status: COMPLETED